Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer

Sang Joon Shin, Hei Cheul Jeung, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Hyun Cheol Chung

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Purpose: The aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens. Methods: Patients received capecitabine, 2,500 mg/m 2/day PO for 14 days (D1-14) and doxorubicin, 30 mg/m2 IV on day 1 every 3 weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0). Results: Forty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1-12) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6 mg/m2/week, respectively. The overall response rate was 6.7% (95% CI, 4.1-12.5%) and the disease control rate was 46.7% (95% CI, 28.6-87.1%) according to an intent-to-treat analysis. The median progression-free survival was 11.3 weeks (95% CI, 5.6-16.7 weeks). The median overall survival was 29.1 weeks (95% CI, 18.3-39.9 weeks) with one-year survival rate of 24%. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1%), neutropenia in two (4.4%), anemia in one (2.2%), and hand-foot syndrome in one patient (2.2%). Conclusions: The combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer.

Original languageEnglish
Pages (from-to)157-165
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Issue number1
Publication statusPublished - 2008 Jan

Bibliographical note

Funding Information:
Acknowledgments This work was supported by the Korea Science and Engineering Foundation (KOSEF) through the Cancer Metastasis Research Center (CMRC) at Yonsei University College of Medicine.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer'. Together they form a unique fingerprint.

Cite this